Functional Deimmunization of Therapeutic Proteins

治疗性蛋白质的功能性去免疫化

• 批准号: 8502706
• 负责人: Chris Bailey-Kellogg
• 金额: $ 28.32万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8502706
• 关键词: Accounting; Address; Agreement; Algorithms; Anaphylaxis; Antibodies; Antineoplastic Agents; Bacteria; Bacterial Infections; Benchmarking; Binding Proteins; Biological Assay; Biological Products; Biological Response Modifier Therapy; Biotechnology; Caring; Communities; Complement; Data; Development; Disease; Diversity Library; Engineering; Enzymes; Epitopes; Evaluation; Exhibits; Future; Genes; Genetic; Goals; Human; Immune; Immune System Diseases; Immune response; Immune system; Individual; Lactamase; Lead; Length; Libraries; Life; Medical; Methodology; Methods; Modeling; Mutation; Myocardial Infarction; Non-Human Protein; Patients; Peptide Receptor; Pharmaceutical Preparations; Point Mutation; Polyethylene Glycols; Production; Protein Analysis; Protein Engineering; Proteins; Public Health; Publishing; Recombinant DNA; Recombinants; Refractory; Relative (related person); Risk; Sequence Analysis; Side; Site-Directed Mutagenesis; Source; Stroke; T-Lymphocyte Epitopes; Techniques; Technology; Testing; Therapeutic; Time; Update; Variant; Virus Diseases; Weight; base; beta-Lactamase; cancer therapy; clinical application; clinical practice; combinatorial; computerized tools; design; drug resistant virus; engineering design; high throughput screening; human disease; humanized antibody; immunogenic; immunogenicity; improved; member; next generation; novel; prospective; protein function; protein structure; receptor binding; research study; response; success; therapeutic protein; thermostability

DESCRIPTION (provided by applicant): The advance of therapeutic proteins represents a revolution in clinical practice, but use of protein drugs requires consideration of their immunogenicity and potential to elicit an anti-biotherapeutic immune response (aBIR) in human patients. Such aBIRs can manifest a range of complications ranging from loss of efficacy to life-threatening anaphylactic shock, and mitigating immunogenicity is a key aspect of biotherapeutic development. While numerous factors influence protein immunogenicity, one critical feature is the source, i.e. proteins of non-human origin are disproportionately immunogenic. Given the immense therapeutic potential of foreign proteins, a variety of deimmunization strategies have been considered. Some methods, such as antibody humanization, are highly effective but limited to a narrow subset of protein classes. Others, such as conjugation to polyethylene glycol, are widely applicable but typically lead to a substantial loss of protein function. Modern protein engineering has enabled genetic approaches wherein immunogenic epitopes are deleted by site-directed mutagenesis, but current methods are costly, time and labor intensive, and have shown limited success. In contrast, computational tools for protein analysis are fast, efficient, and increasingly accurate. In this proposal, it is hypothesized that novel optimization algorithms can be leveraged to design protein variants that simultaneously reduce protein immunogenicity while maintaining high level functionality. Aim 1 will test the hypothesis that for a given therapeutic protein, there exists a predictable and optimizable spectrum of trade-offs between the competing goals of reduced immunogenicity and high-level functionality. Ten engineered variants of a 2-lactamase therapeutic candidate (P992L) will be designed with a range of weights on the two objective functions: deimmunization vs. functionality. The P992L variants will be produced and assayed for activity, thermostability and immunogenicity. Aim 2 will test the hypothesis that combinatorial protein libraries can be computationally optimized for functional therapeutic candidates. The optimization algorithms will be extended to enable design of deimmunized combinatorial protein libraries. Five libraries, having a range of relative weights for deimmunization vs. functionality, will be constructed and screened with a high throughput functional assay. The proportion of library members exhibiting high level functionality will be quantitatively determined, and the results will be benchmarked against the original library design parameters. Aim 3 seeks to evaluate and refine the models of immunogenicity and functionality that underlie the objective functions of the design algorithm. An enhanced model of protein structure will be integrated into the design algorithm, and a new panel of P992L proteins will be constructed and experimentally evaluated. The results of these analyses will subsequently be used to update the optimization objectives and algorithm, and produce new variants, thereby closing the loop between computation and experiment. Successfully achieving these aims will yield broadly applicable algorithms for engineering powerful and immune-tolerant therapeutic proteins.

描述（由申请人提供）：治疗性蛋白质的进步代表了临床实践的一场革命，但蛋白质药物的使用需要考虑其免疫原性以及在人类患者中引发抗生物治疗性免疫反应（aBIR）的潜力。这种 aBIR 可能会出现一系列并发症，从疗效丧失到危及生命的过敏性休克，而减轻免疫原性是生物治疗开发的一个关键方面。虽然影响蛋白质免疫原性的因素有很多，但一个关键特征是来源，即非人类来源的蛋白质具有不成比例的免疫原性。鉴于外源蛋白的巨大治疗潜力，人们考虑了多种去免疫策略。有些方法（例如抗体人源化）非常有效，但仅限于一小部分蛋白质类别。其他的，例如与聚乙二醇的缀合，广泛适用，但通常会导致蛋白质功能的大量丧失。现代蛋白质工程已经使遗传方法成为可能，其中通过定点诱变删除免疫原性表位，但目前的方法成本高昂、时间和劳动力密集，并且取得的成功有限。相比之下，蛋白质分析的计算工具快速、高效且越来越准确。在该提案中，假设可以利用新颖的优化算法来设计蛋白质变体，在保持高水平功能的同时降低蛋白质免疫原性。目标 1 将检验以下假设：对于给定的治疗性蛋白质，在降低免疫原性和高水平功能性的竞争目标之间存在可预测和可优化的权衡范围。 2-内酰胺酶候选治疗药物 (P992L) 的十种工程变体将根据两个目标函数（去免疫与功能）的一系列权重进行设计。将生产 P992L 变体并对其活性、热稳定性和免疫原性进行分析。目标 2 将测试组合蛋白库可以针对功能性治疗候选物进行计算优化的假设。优化算法将得到扩展，以实现去免疫组合蛋白库的设计。将构建五个文库，具有一系列去免疫与功能的相对权重，并通过高通量功能测定进行筛选。将定量确定表现出高级功能的库成员的比例，并将结果与​​原始库设计参数进行基准比较。目标 3 旨在评估和完善作为设计算法目标函数基础的免疫原性和功能模型。蛋白质结构的增强模型将被整合到设计算法中，并且将构建一组新的 P992L 蛋白质并进行实验评估。这些分析的结果随后将用于更新优化目标和算法，并产生新的变体，从而闭合计算和实验之间的循环。成功实现这些目标将产生广泛适用的算法，用于工程强大且免疫耐受的治疗蛋白。